Viatris Inc. (VTRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
VTRS POWR Grades
- Value is the dimension where VTRS ranks best; there it ranks ahead of 96.07% of US stocks.
- The strongest trend for VTRS is in Value, which has been heading up over the past 179 days.
- VTRS's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).
VTRS Stock Summary
- VTRS's went public 34.3 years ago, making it older than 90.57% of listed US stocks we're tracking.
- Price to trailing twelve month operating cash flow for VTRS is currently 4.48, higher than only 14.58% of US stocks with positive operating cash flow.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VTRS comes in at 18.47% -- higher than that of 90.64% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Viatris Inc, a group of peers worth examining would be TFX, XYL, CW, SNN, and WAB.
- Visit VTRS's SEC page to see the company's official filings. To visit the company's web site, go to www.viatris.com.
VTRS Valuation Summary
- In comparison to the median Healthcare stock, VTRS's price/sales ratio is 71.05% lower, now standing at 1.1.
- Over the past 243 months, VTRS's price/earnings ratio has gone down 34.
- VTRS's price/sales ratio has moved down 3.4 over the prior 243 months.
Below are key valuation metrics over time for VTRS.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
VTRS | 2021-08-31 | 1.1 | 0.8 | -8.6 | -49.6 |
VTRS | 2021-08-30 | 1.1 | 0.8 | -8.5 | -49.3 |
VTRS | 2021-08-27 | 1.1 | 0.8 | -8.5 | -49.3 |
VTRS | 2021-08-26 | 1.1 | 0.8 | -8.4 | -49.1 |
VTRS | 2021-08-25 | 1.1 | 0.8 | -8.6 | -49.5 |
VTRS | 2021-08-24 | 1.1 | 0.8 | -8.7 | -49.7 |
VTRS Growth Metrics
- Its 2 year revenue growth rate is now at -2.09%.
- The year over year revenue growth rate now stands at 18.35%.
- The 4 year cash and equivalents growth rate now stands at -52.28%.

The table below shows VTRS's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 17,886.3 | 3,016.9 | -1,269.1 |
2021-09-30 | 17,168.2 | 2,530 | -1,921.1 |
2021-06-30 | 15,603.7 | 1,969.4 | -2,046.9 |
2021-03-31 | 13,757.1 | 1,789.5 | -1,728.3 |
2020-12-31 | 11,946 | 1,231.8 | -669.9 |
2020-09-30 | 11,514.3 | 1,882.3 | 266.4 |
VTRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VTRS has a Quality Grade of D, ranking ahead of 8.02% of graded US stocks.
- VTRS's asset turnover comes in at 0.298 -- ranking 155th of 682 Pharmaceutical Products stocks.
- CRIS, KDNY, and AGIO are the stocks whose asset turnover ratios are most correlated with VTRS.
The table below shows VTRS's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.298 | 0.277 | -0.030 |
2021-03-31 | 0.302 | 0.292 | -0.027 |
2020-12-31 | 0.312 | 0.318 | -0.011 |
2020-09-30 | 0.375 | 0.363 | 0.058 |
2020-06-30 | 0.375 | 0.356 | 0.052 |
2020-03-31 | 0.374 | 0.344 | 0.047 |
VTRS Price Target
For more insight on analysts targets of VTRS, see our VTRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $20.21 | Average Broker Recommendation | 1.72 (Moderate Buy) |
VTRS Stock Price Chart Interactive Chart >
VTRS Price/Volume Stats
Current price | $12.05 | 52-week high | $15.92 |
Prev. close | $11.84 | 52-week low | $9.66 |
Day low | $11.84 | Volume | 4,156,405 |
Day high | $12.06 | Avg. volume | 13,032,235 |
50-day MA | $10.84 | Dividend yield | 4.05% |
200-day MA | $12.96 | Market Cap | 14.61B |
Viatris Inc. (VTRS) Company Bio
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn, a division of Pfizer, on November 16, 2020. (Source:Wikipedia)
Latest VTRS News From Around the Web
Below are the latest news stories about Viatris Inc that investors may wish to consider to help them evaluate VTRS as an investment opportunity.
Will Viatris Q4 results bring earnings surprise?Viatris (NASDAQ:VTRS) is scheduled to announce Q4 earnings results on Friday, February 25th, after market close. The consensus EPS Estimate is $0.75 and the consensus Revenue Estimate is $4.34B Over the last 2 years, VTRS has beaten EPS estimates 100% of the time and has beaten revenue estimates 38% of... |
Why Viatris (VTRS) Might Surprise This Earnings SeasonViatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
Theravance's (TBPH) Q4 Earnings and Sales Miss EstimatesTheravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year. |
Viatris (VTRS) Stock Moves -1.58%: What You Should KnowViatris (VTRS) closed the most recent trading day at $14.32, moving -1.58% from the previous trading session. |
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen. |
VTRS Price Returns
1-mo | 18.31% |
3-mo | -16.27% |
6-mo | -3.73% |
1-year | -17.73% |
3-year | N/A |
5-year | N/A |
YTD | -9.28% |
2021 | -26.12% |
2020 | N/A |
2019 | N/A |
2018 | N/A |
2017 | N/A |
VTRS Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Loading social stream, please wait...